Showing results (131-140 of 219) with videos related to

Sort By:
Pageof 22
Cancers|September 27, 2025
Correction: Shoushtari et al. A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma. Cancers 2021, 13, 5504Alexander N Shoushtari, Shaheer Khan, Kimberly Komatsubara, et al.
Science Translational Medicine|October 31, 2014
Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probeEvan Phillips, Oula Penate-Medina, Pat B Zanzonico, et al.
Investigational New Drugs|February 24, 2021
LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trialAfshin Dowlati, R Donald Harvey, Richard D Carvajal, et al.
Cancers|November 13, 2021
A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal MelanomaAlexander N Shoushtari, Shaheer Khan, Kimberly Komatsubara, et al.
Investigational New Drugs|August 7, 2012
Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanomaPatrick A Ott, Richard D Carvajal, Neeta Pandit-Taskar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2009
Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumorsDana Rathkopf, Mark A Dickson, Darren R Feldman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2022
Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal MelanomaRichard D Carvajal, Paul Nathan, Joseph J Sacco, et al.
Head & Neck|January 26, 2020
MicroRNA-based risk scoring system to identify early-stage oral squamous cell carcinoma patients at high-risk for cancer-specific mortalityAngela J Yoon, Shuang Wang, David I Kutler, et al.
Melanoma Management|August 22, 2020
Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2)James Sun, Brian R Gastman, Lucy McCahon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2013
Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanomaFederica Catalanotti, David B Solit, Melissa P Pulitzer, et al.
Pageof 22